SLRN241220C2500
- 0.00
- 0.000.00%
Acelyrin Newsroom
UCB Gets FDA Approval for Bimzelx for Hidradenitis Suppurativa
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
Vikram Purohit's Hold Rating on ACELYRIN, INC.: Awaiting Key Data and Trial Progress for Future Stock Movement
ACELYRIN Is Maintained at Neutral by HC Wainwright & Co.
Acelyrin Analyst Ratings
Acelyrin Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Acelyrin(SLRN.US) With Buy Rating
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $8 to $20
Strategic Shifts and Promising Developments Drive ACELYRIN's Potential Share Doubling
Acelyrin's Phase 3 Trial Progress and Uncertainties Lead to Hold Rating
Express News | ACELYRIN, Inc. : H.c. Wainwright Raises Target Price to $8 From $6
ACELYRIN, INC. Advances Key Drug Developments
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript Summary
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript
ACELYRIN, INC. Receives Buy Rating From Tyler Van Buren Due to Clinical Progress and Strategic Advancements
Express News | ACELYRIN Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing
Acelyrin Q3 Net Loss Narrows
Acelyrin | 10-Q: Q3 2024 Earnings Report